Pharmacy joins with engineering to make inhaled medications more effective for infants
Pharmaceutical aerosols are painless, fast-acting and less likely to cause side effects than medicines delivered via pills or injections. Yet inhaled therapies are often avoided because of the challenges associated with targeting how aerosol particles are deposited within the lung.
“Current inhalers produce fairly large particles, so approximately 90 percent of the medication gets lost in the mouth and throat. It’s swallowed and wasted. This prevents many medications from being delivered through the inhalation route, even though there are a number of advantages to be gained, such as improved efficacy and reduced side effects,” said Worth Longest, Ph.D., the Louis S. and Ruth S. Harris Exceptional Scholar Professor in the Department of Mechanical and Nuclear Engineering in the VCU College of Engineering.
Simply making the particles smaller isn’t a solution.
“The problem with making the particles smaller is that they go in really well — but they also come straight back out during exhalation,” said Michael Hindle, Ph.D., the Peter R. Byron Distinguished Professor in the VCU School of Pharmacy.
With three National Institutes of Health R01 grants totaling more than $7 million, Longest and Hindle are applying a combined engineering and pharmaceutical approach to make inhaled medications more effective and available.
In “High-Efficiency Aerosol Delivery Using the Excipient Enhanced Growth Concept: A Human Proof of Concept Study,” Longest and Hindle have created a novel platform that produces particles that are tiny when they enter the lungs — but grow in size as they travel down the warm, humid airways. This platform comprises a device that uses a mixer-heater to produce tiny particles, about one-fifth the size of those from conventional inhalers.
With this delivery concept, a pharmaceutical powder or liquid is enhanced with a hygroscopic excipient, essentially a substance that attracts water. “Your lungs are full of water,” Hindle said. “So if you put something inside your lungs that likes water, it’s going to swell and grow in size and not be expelled.” Using sodium chloride — salt — as the hygroscopic excipient, they have tested their system in vitro.
The results have been promising.
“We’ve flipped the needle,” Longest said. “Previously, only 10 percent of the initial dose would reach the lung, and that 10 percent was poorly targeted within different lung regions. With our approach, you can get 90 percent in and distribute that 90 percent evenly, or target a specific lung region.”
The researchers will begin testing their method on adults in two human proof-of-concept trials beginning in late 2019 and early 2020.
In two separate but related NIH studies, Longest and Hindle are adapting this concept for patients ranging in age from newborn to 6 years old. Each project proposes a device approximately the size of a lipstick tube that contains a pediatric formulation (liquid or powder) enhanced with a hygroscopic excipient. There are currently no inhalers on the market specifically designed for children or infants, even though their inhaling patterns and volumes differ from those of adults. Pediatric patients therefore must use adult-sized devices.
One study focuses on targeted lung delivery of the antibiotic tobramycin to children with cystic fibrosis, a population prone to respiratory infection because of overproduction of mucus in the lungs. Pediatric cystic fibrosis patients with lung infections usually receive the medication via, 20-minute nebulizer treatments daily, sometimes up to four per day.
Longest and Hindle’s proposed alternative is a pediatric dry powder inhaler that is fast and easy to use. Because its particles are engineered to reach the deep lung, it is expected to eradicate infection more efficiently because there is less risk of resistant strains of bacteria forming in undertreated regions of the lung.
The other study focuses on delivery of surfactant aerosols to premature infants. Surfactant is a substance found in healthy lungs that keeps the tissue supple enough to expand and contract properly. The respiratory system is among the last to develop in utero, so in newborns and preemies, this substance is sometimes not fully developed — or not present at all.
When these infants experience severe respiratory distress, the current protocol is to intubate and administer large doses of liquid surfactant to the lung by way of the throat. This highly invasive and potentially dangerous procedure causes distress and blood pressure fluctuations. In this third NIH-funded study, the researchers are also developing a tiny, small volume nebulizer and a dry powder inhaler for efficient, noninvasive respiratory support for infants.
These in-vitro studies are titled “High-Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis” and “High-Efficiency Delivery of Surfactant Aerosols to Infants without Intubation.”
They involve collaborators from across VCU, including Jürgen Venitz, M.D., Ph.D., vice chair and professor of pharmaceutics in the School of Pharmacy; Kelly Dodson, Ph.D., associate professor of otolaryngology; Bruce Rubin, M.D., the Jessie Ball DuPont Distinguished Professor and chair of pediatrics; Douglas Willson, M.D., professor of pediatrics; Robert Meredith, M.D., assistant professor of radiology; Rebecca Heise, Ph.D., associate professor of biomedical engineering; Dennis Ohman, Ph.D., professor of microbiology and immunology; Jamal Zweit, Ph.D., director of the VCU Center for Molecular Imaging; Sundaresan Gobalakrishnan, Ph.D., assistant professor of molecular imaging and radiology; Aamer Syed, M.D., assistant professor of internal medicine; Christine DeWilde, R.N., associate director of clinical research programs in the Johnson Center for Critical Care and Pulmonary Research; and Anna Priday, regulatory manager in the Johnson Center.